MetaCap

MindWalk (HYFT) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MindWalk (HYFT) has outperformed Serina Therapeutics (SER) over the past year, losing 59.0% versus a loss of 71.9%. Over five years, HYFT leads with a -89.3% price change compared with -95.6% for SER. MindWalk is the larger company by market cap ($32.6 million vs $29.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HYFT-59.02%SER-71.93%
+73%-3%-79%
Nov 21, 20251 yearNov 20, 2026
HYFT-87.65%SER-96.03%
+46%-28%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HYFT versus SER key metrics
MetricHYFTSER
Share price$0.6844$1.12
Market cap$32.56M$29.76M
1-day change-14.27%-6.67%
YTD return-62.40%-41.45%
1-year return-59.02%-71.93%
5-year return-89.34%-95.64%
EPS (TTM)$-0.26$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$130.00K
Revenue growth (YoY)—+132.14%
Net income (latest FY)—$-19.18M
Operating margin—-18478.46%
Net margin—-14755.38%
52-week high$2.99$4.26
52-week low$0.64$1.06
Distance from 52-week high-77.11%-73.71%
Analyst consensusnonenone
Avg. price target upside+532.67%+748.21%
Average volume257.86K68.98K
Shares outstanding47.57M26.57M
Employees7416
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HYFT has outperformed SER by 12.9 percentage points over the past year.

About MindWalk

HYFT stock →

MindWalk Holdings Corp. operates as a bio-native AI company.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

HYFT vs SER FAQ

Which is bigger, MindWalk or Serina Therapeutics?

MindWalk (HYFT) is larger, with a market capitalization of $32.56M compared with $29.76M for Serina Therapeutics (SER).

Which stock has performed better over the past year, HYFT or SER?

HYFT returned -59.02% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.

Are MindWalk and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons